Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08AAV
|
|||
| Former ID |
DIB004590
|
|||
| Drug Name |
AZD-3514
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0] | Phase 1 | [1] | |
| Company |
AstraZeneca plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H32F3N7O2
|
|||
| Canonical SMILES |
CC(=O)N1CCN(CC1)CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5C(F)(F)F)CC4
|
|||
| InChI |
1S/C25H32F3N7O2/c1-18(36)33-14-12-32(13-15-33)16-17-37-21-4-2-19(3-5-21)20-8-10-34(11-9-20)23-7-6-22-29-30-24(25(26,27)28)35(22)31-23/h2-5,20H,6-17H2,1H3
|
|||
| InChIKey |
JMEYDSHPKCSIJC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1240299-33-5
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01351688) An Open Label Prostate Cancer Study in Japanese Patients. U.S. National Institutes of Health. | |||
| REF 2 | AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.